Driving the Future of Intervention™

microbot medical

Safe Harbor Statement

This document (together with any oral statements made in connection with this document) contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, relating to future events or the future financial performance and operations of Microbot Medical, Inc. and its subsidiaries. Forward-looking statements, which involve assumptions and describe Microbot's intent, belief or current expectations about its business opportunities, prospects, performance and results, are generally identifiable by use of the words "may," "could," "should," "will," "would," "expect," "anticipate," "plan," "potential," "estimate," "believe," "intend," "project," "forecast," the negative of such words and other variations on such words or similar terminology. All statements other than statements of historical fact could be deemed forward-looking statements, including, but not limited to: market conditions; risks inherent in the commercialization of the LIBERTY® Endovascular Robotic System, and in the development of future versions of or applications for the system; uncertainty in the results of regulatory pathways and regulatory approvals; uncertainty resulting from political, social and geopolitical conditions; disruptions resulting from new and ongoing hostilities between Israel and the Palestinians, Iran and other neighboring countries; maintenance of intellectual property rights; our ability to leverage the experience of Microbot's management team; and any statements or assumptions underlying any of the items mentioned. These forward-looking statements are not guarantees of future performance and by their nature involve known and unknown risks and uncertainties that may cause actual opportunities, prospects, performance and results to vary from those presented in this document, and those variances may be material. In evaluating such statements, prospective investors should carefully consider the various risks and uncertainties identified in Microbot's public filings with the Securities and Exchange Commission (the "SEC"), such as market risk, liquidity risk, competitive risk, regulatory risk and other commonly recognized forms of risk relating to Microbot and its securities. In light of these risks, uncertainties and assumptions, the forward-looking events discussed in this document might not occur. Microbot is not obligated to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.This presentation shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of Microbot's securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

Driving the Future of Intervention

Large and Emergent Market

Growing Unmet Needs

A New Robotics Category

Building for Comprehensive Growth

Existing Financial Strength

The Reason to Believe

Large and Emergent Market

- **~6 million annual endovascular procedures performed in the US (~15 million worldwide)**
- **>$40B spent annually** in the US
- Performed by **15,000 physicians**
  - 9,000 interventional cardiologists
  - 3,000 interventional radiologists[1]
  - 3,000 vascular surgeons
- Performed at **8,000 facilities**
  - 3,500 hospitals
  - 4,500 ambulatory centers (ASCs/OBLs)
- Many **endovascular procedures are emergent**, life and limb saving interventions



Source: AcuityMD procedure and physician database
1. Includes interventional neuroradiologists which is a sub-specialty of IR

USA endovascular market

~6M Annual Procedures

- Neuro ~500K
- Coronary ~3M
- Peripheral ~2.5M

Endovascular Anatomy



Current procedure utilization



Kidney
Renal Angiogram

Prostate
Prostate Artery Embolization (PAE)

Knee
Genicular Artery Embolization (GAE)

Liver
Y90 Mapping
Y90 Delivery

Uterus
Uterine Artery Embolization (UAE)

Leg / Peripheral Arteries
ATK / BTK Revascularization
Above the Knee (ATK) Below the Knee (BTK)

Growing Unmet Needs

AMA's 2026 public health initiative calls for expanded **radiation safety protections** and **ergonomic workplace design** to reduce clinician injury and improve long-term workforce health.[1]

Radiation & Ergonomic Risks[2]

Interventionalists have:

- 6× higher risk of cataracts
- 3× higher risk of malignancy

Ergonomic / Musculoskeletal Risks:

- 66% reported musculoskeletal pain related to wearing lead protective equipment
- 60% reported at least one orthopedic injury

Staff Shortage

- IR is ranked 2nd in specialties facing the greatest physician shortages[3]
- Healthcare faces staff shortages of 85K+ by 2036[4]
- Nearly 50% of physicians report burnout[4]
- 1 in 5 physicians report experiencing depression, exacerbating workforce gaps[4]

Access to Quality Care[5]

- 20% of Americans live in rural areas where only 10% of doctors practice
- 80% of rural Americans are medically underserved
- ~200 rural hospitals have closed since 2005

1 AMA adopts new public health policies to improve health of nation | American Medical Association
2. https://evtoday.com/articles/2025-early-career-insights-2/radiation-safety-dont-wait-until-its-too-late?utm_source=linkedin&utm_medium=newsletter&utm_campaign=etDE1125_Gore
3. https://axuall.com/wp-content/uploads/2025/06/Axuall-_-2025-Clinician-Workforce-Insights-Report-final.pdf
4. https://nihcm.org/newsletter/rising-healthcare-workforce-shortage
5. https://nihcm.org/publications/rural-health-needs-in-america-challenges-and-solutions
6. https://www.cvironline.org/

Market Support

AMA Join Renew

PRESS CENTER > PRESS RELEASES

AMA adopts new public health po nation

Nov 18, 2025 6 Min Read

Expanding efforts to protect healt ionizing radiation

As the use of imaging and interventional procedures that rely on adopted new policy to strengthen protections for health care pro exposure.

NEURONEWS

EATURES NEUROMODULATION PROFILES VIDEOS EVENTS SUPPLEMENTS PAST ISSUES SUBSCRIBE

ties call for new standard in ection

ESOC 2026 12th European Stroke Organisation Conference

REGISTER NOW

IONS PATIENTS

CH MEETINGS

SOCIETY

EDUCATION

CIRSE and the Society of Interventional Radiology (SIR) have released an updated joint guidelines document on radiation protection. To learn about key features of the guidelines, CIRSE Insider spoke with the authors: Dr. Donald Miller and Prof. Peter Reimer.

A New Robotics Category

Fully Disposable & Single-use Robotic System is Designed for Access and Adoption

External Benefits

- Single-use, disposable system eliminates capital and infrastructure costs
- Sterile, ready-to-use design enables rapid setup
- No capital investment removes upfront costs and long-term risks
- No service contracts/annual service agreements required

A New Robotics Category

Fully Disposable & Single-use Robotic System is Designed for Access and Adoption

Internal Benefits

- First mover advantage
- Faster sales cycle for quicker acquisition
- Predictable recurring revenue from utilization
- Disposable only components reduce upfront inventory expenses
- No field service/parts/warehouses needed, further reducing operational expenses

U.S. Focused



** As of May 14, 2026

Q1 2026 Accounts



** As of May 14, 2026

Q2 2026 Accounts



** As of May 14, 2026

Global Regulatory Landscape



*Note: While FDA clearance may accelerate registration time and reduces testing burdens, almost all of these countries still require local registration, labeling translation, and appointment of a local authorized representative before the device can be legally marketed in their jurisdiction.

*** Territories that Microbot Medical is currently exploring as another step in the regulatory expansion

Global Intellectual Property Portfolio

21
patents issued worldwide

53
patents pending

LIBERTY® is protected by a strong and growing intellectual property portfolio.

Building for Comprehensive Growth

Future growth will come from access to new markets (EMEA, Canada, etc.), spaces (cardiology, neurovascular) and usability (tele-intervention)

Active R&D Pipeline: Focused on next-generation robotic system that allows for increased usability in existing space (deep) and entering new spaces (wide).

Ongoing Development: Tele-robotics and autonomous robotics programs in progress.

Build a direct sales team in the U.S. from 8 to 12 territories by end of the year.

Expand to new markets: Establish commercial and operational infrastructure to support expansion into EMEA (Europe, Middle East, Asia).

Pursue CE Mark: Supplement FDA clearance to enter markets based on respective regulatory requirements.

liberty
Endovascular Robotic System

Financial Strength

- **Capital-efficient operating model** by eliminating upfront and ongoing expensive equipment inventory, logistics, and field service.
- **Frees capital to invest** in high-return growth drivers, including Sales, Marketing, and Pipeline Development, enhancing shareholder value.
- **Strong balance sheet** with ~$72M in cash Q1 2026 and a ~$2.5M/month burn rate in 2026, providing a favorable cash runway.

The Reason to Believe

- **FDA Clearance** Only FDA Cleared Single-Use Peripheral Robotic System
- **Full Market Release (FMR)** Successful LMR allowed company to launch FMR in April 2026 as planned
- **Growing Customer base –** Adoption by Leading Academic Centers has increased utilization in multiple sales territories
- **Enhanced Balance Sheet** ~ $72M available to Drive Commercialization Activities